Halozyme Therapeutics (HALO) Financials

$61.28 -0.11 (-0.18%)

Closing price 04/15/2025 04:00 PM Eastern

Extended Trading

$60.75 -0.53 (-0.86%)

As of 04/15/2025 07:56 PM Eastern

Annual Income Statements for Halozyme Therapeutics

This table shows Halozyme Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-32	-103	63	-80	-72	129	403	202	282	444
Consolidated Net Income / (Loss)	-32	-103	63	-80	-72	129	403	202	282	444
Net Income / (Loss) Continuing Operations	-32	-103	63	-80	-72	129	403	202	282	444
Total Pre-Tax Income	-32	-102	62	-80	-72	129	249	249	348	557
Total Operating Income	-27	-83	81	-69	-68	144	276	268	338	551
Total Gross Profit	106	113	285	142	150	224	362	521	637	856
Total Revenue	135	147	317	152	196	268	443	660	829	1,015
Operating Revenue	135	147	317	152	196	268	443	660	829	1,015
Total Cost of Revenue	29	33	31	10	46	43	81	139	192	159
Operating Cost of Revenue	29	33	31	10	46	43	81	139	192	159
Total Operating Expenses	133	197	204	211	218	80	86	253	299	304
Selling, General & Admin Expense	40	46	54	61	77	46	50	144	149	154
Research & Development Expense	93	151	151	150	141	34	36	67	76	79
Amortization Expense	-	-	-	-	-	0.00	0.00	43	74	71
Total Other Income / (Expense), net	-4.78	-19	-19	-10	-4.64	-15	-27	-19	11	5.66
Interest Expense	5.20	20	22	18	12	20	28	20	19	18
Interest & Investment Income	-	-	-	-	-	-	0.00	0.00	13	0.00
Other Income / (Expense), net	0.42	1.33	2.59	7.58	6.99	5.43	1.10	1.05	16	24
Income Tax Expense	0.00	1.16	-1.36	0.54	-0.01	0.22	-154	47	67	113
Basic Earnings per Share	($0.25)	($0.81)	$0.46	($0.56)	($0.50)	$0.95	$2.86	$1.48	$2.13	$3.50
Weighted Average Basic Shares Outstanding	126.70M	127.96M	136.42M	143.60M	144.33M	136.21M	140.65M	136.84M	131.93M	126.83M
Diluted Earnings per Share	($0.25)	($0.81)	$0.45	($0.56)	($0.50)	$0.91	$2.74	$1.44	$2.10	$3.43
Weighted Average Diluted Shares Outstanding	126.70M	127.96M	139.07M	143.60M	144.33M	141.46M	146.80M	140.61M	134.20M	129.42M
Weighted Average Basic & Diluted Shares Outstanding	126.70M	127.20M	0.00	143.60M	144.33M	135.28M	137.70M	135.37M	126.82M	123.15M

This table shows Halozyme Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	62	58	40	75	82	85	77	93	137	137
Consolidated Net Income / (Loss)	62	58	40	75	82	85	77	93	137	137
Net Income / (Loss) Continuing Operations	62	58	40	75	82	85	77	93	137	137
Total Pre-Tax Income	74	71	52	93	102	101	96	118	165	178
Total Operating Income	83	75	54	94	88	101	96	117	163	176
Total Gross Profit	162	139	127	171	161	178	168	192	241	256
Total Revenue	209	181	162	221	216	230	196	231	290	298
Operating Revenue	209	181	162	221	216	230	196	231	290	298
Total Cost of Revenue	47	42	35	50	55	52	28	40	49	42
Operating Cost of Revenue	47	42	35	50	55	52	28	40	49	42
Total Operating Expenses	78	65	73	77	73	77	72	75	77	80
Selling, General & Admin Expense	34	38	37	39	35	38	35	36	41	42
Research & Development Expense	17	23	18	20	17	21	19	21	18	20
Amortization Expense	27	4.55	18	18	20	18	18	18	18	18
Total Other Income / (Expense), net	-9.59	-3.72	-1.56	-1.30	13	0.14	0.49	0.51	1.95	2.71
Interest Expense	10	4.57	4.54	4.49	4.51	5.22	4.51	4.52	4.52	4.54
Other Income / (Expense), net	0.64	0.85	2.98	3.19	4.79	5.36	4.99	5.03	6.47	7.25
Income Tax Expense	12	13	13	18	20	16	19	24	28	41
Basic Earnings per Share	$0.45	$0.43	$0.29	$0.57	$0.62	$0.65	$0.61	$0.73	$1.08	$1.08
Weighted Average Basic Shares Outstanding	136.53M	136.84M	135.03M	131.73M	131.97M	131.93M	126.94M	127.12M	126.85M	126.83M
Diluted Earnings per Share	$0.44	$0.41	$0.29	$0.56	$0.61	$0.64	$0.60	$0.72	$1.05	$1.06
Weighted Average Diluted Shares Outstanding	139.39M	140.61M	137.90M	133.54M	134.08M	134.20M	128.89M	129.22M	130.13M	129.42M
Weighted Average Basic & Diluted Shares Outstanding	135.21M	135.37M	131.68M	131.92M	132.10M	126.82M	127.27M	126.68M	127.23M	123.15M

This table details how cash moves in and out of Halozyme Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	-18	23	102	-111	62	28	-29	115	-116	-2.52
Net Cash From Operating Activities	-37	-50	134	-50	-85	55	299	240	389	479
Net Cash From Continuing Operating Activities	-37	-50	134	-49	-85	55	299	240	389	479
Net Income / (Loss) Continuing Operations	-32	-103	63	-80	-72	129	403	202	282	444
Consolidated Net Income / (Loss)	-32	-103	63	-80	-72	129	403	202	282	444
Depreciation Expense	1.68	2.41	2.16	2.39	4.07	3.28	3.00	6.49	11	10
Amortization Expense	1.24	16	1.46	-1.55	0.02	15	5.90	52	75	67
Non-Cash Adjustments To Reconcile Net Income	22	26	31	39	33	12	40	26	25	46
Changes in Operating Assets and Liabilities, net	-30	8.38	37	-8.71	-51	-104	-152	-46	-4.17	-89
Net Cash From Investing Activities	5.89	-77	-164	2.49	-5.55	78	-406	-487	-97	-263
Net Cash From Continuing Investing Activities	5.89	-77	-164	2.49	-5.55	78	-406	-487	-97	-263
Purchase of Property, Plant & Equipment	-2.36	-3.14	-1.54	-4.66	-4.04	-2.50	-1.46	-4.81	-15	-11
Acquisitions	-	-	-	-	-	0.00	0.00	-999	0.00	0.00
Purchase of Investments	-71	-155	-398	-311	-390	-226	-653	-255	-293	-648
Sale of Property, Plant & Equipment	-	-	-	0.00	0.00	1.08	0.00	26	0.00	0.00
Sale and/or Maturity of Investments	80	82	236	318	388	306	248	746	211	396
Net Cash From Financing Activities	13	151	132	-64	153	-106	78	362	-408	-219
Net Cash From Continuing Financing Activities	13	151	132	-64	153	-106	78	362	-408	-219
Repayment of Debt	0.00	-54	-16	-78	-108	-20	-369	-455	-13	0.00
Repurchase of Common Equity	-	-	0.00	0.00	-200	-150	-350	-200	-402	-250
Issuance of Debt	0.00	203	0.00	0.00	447	0.00	785	1,072	0.00	0.00
Issuance of Common Equity	13	1.87	148	14	14	63	13	14	7.88	31
Other Financing Activities, net	-	-	-	-	-	0.00	0.00	-69	0.00	0.00
Cash Interest Paid	3.78	3.89	20	17	9.03	6.53	3.30	6.11	11	11
Cash Income Taxes Paid	0.00	1.44	3.02	0.22	0.19	0.18	-0.38	16	32	81

This table details how cash moves in and out of Halozyme Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	56	87	-138	124	53	-156	46	23	-34	-38
Net Cash From Operating Activities	70	82	87	67	132	102	129	56	115	178
Net Cash From Continuing Operating Activities	70	82	87	67	132	102	129	56	115	178
Net Income / (Loss) Continuing Operations	62	58	40	75	82	85	77	93	137	137
Consolidated Net Income / (Loss)	62	58	40	75	82	85	77	93	137	137
Depreciation Expense	2.01	2.56	2.62	2.79	2.74	2.93	2.44	2.57	2.60	2.65
Amortization Expense	31	6.51	19	18	21	17	17	17	16	17
Non-Cash Adjustments To Reconcile Net Income	8.81	6.09	12	4.48	-4.63	14	10	11	13	12
Changes in Operating Assets and Liabilities, net	-34	9.60	14	-33	32	-17	23	-68	-54	10
Net Cash From Investing Activities	-1.01	-1.75	-60	55	-83	-8.29	-83	-42	-167	29
Net Cash From Continuing Investing Activities	-1.01	-1.75	-60	55	-83	-8.29	-83	-42	-167	29
Purchase of Property, Plant & Equipment	-1.01	-2.34	-11	1.62	-2.94	-2.60	-3.55	-2.58	-1.52	-3.05
Purchase of Investments	-	-30	-110	-	-162	-21	-199	-93	-304	-51
Sale and/or Maturity of Investments	-	20	61	53	81	16	120	54	138	84
Net Cash From Financing Activities	-12	6.33	-165	2.45	4.10	-250	-0.49	9.48	19	-246
Net Cash From Continuing Financing Activities	-12	6.33	-165	2.45	4.10	-250	-0.49	9.48	19	-246
Repurchase of Common Equity	-200	-0.00	-150	-	-	-252	0.00	-	-	-250
Issuance of Common Equity	2.64	6.97	-	-	4.10	2.38	-	-	19	3.59

This table presents Halozyme Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	182	262	520	440	566	580	1,104	1,842	1,733	2,063
Total Current Assets	172	257	510	428	543	555	926	739	746	1,085
Cash & Equivalents	43	67	169	58	120	148	119	234	118	116
Short-Term Investments	65	138	300	297	301	220	622	129	218	480
Accounts Receivable	32	16	22	30	59	98	91	231	234	308
Inventories, net	9.49	15	5.15	23	29	61	54	100	128	142
Prepaid Expenses	22	21	14	21	33	28	40	45	49	39
Plant, Property, & Equipment, net	3.94	4.26	3.52	7.47	11	0.00	0.00	0.00	0.00	0.00
Total Noncurrent Assets	6.07	0.72	6.05	4.93	12	25	178	1,102	987	978
Goodwill	-	-	-	-	-	-	0.00	409	417	417
Intangible Assets	-	-	-	-	-	-	0.00	547	473	402
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	-	0.00	155	44	4.39	3.86
Other Noncurrent Operating Assets	5.57	0.22	5.55	4.43	11	25	22	102	93	156
Total Liabilities & Shareholders' Equity	182	262	520	440	566	580	1,104	1,842	1,733	2,063
Total Liabilities	139	294	312	191	474	429	907	1,672	1,649	1,700
Total Current Liabilities	62	55	131	149	86	421	117	131	112	139
Accounts Payable	4.50	3.58	7.95	4.08	6.43	1.93	1.54	18	12	10
Accrued Expenses	27	29	40	50	56	20	24	100	101	129
Total Noncurrent Liabilities	76	239	180	42	388	7.49	790	1,541	1,537	1,561
Long-Term Debt	28	199	125	35	383	0.00	787	1,493	1,499	1,506
Other Noncurrent Operating Liabilities	4.44	0.36	0.81	2.12	4.18	3.47	0.54	48	38	55
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	43	-32	208	249	92	151	197	170	84	364
Total Preferred & Common Equity	43	-32	208	249	92	151	197	170	84	364
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	43	-32	208	249	92	151	197	170	84	364
Common Stock	526	553	731	781	695	626	256	28	2.54	0.12
Retained Earnings	-483	-585	-522	-531	-604	-475	-59	143	91	360
Accumulated Other Comprehensive Income / (Loss)	-0.10	-0.01	-0.45	-0.28	0.24	0.02	-0.62	-0.92	-9.28	3.83

This table presents Halozyme Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	1,865	1,699	1,810	1,893	1,842	1,969	2,118
Total Current Assets	653	615	766	879	874	988	1,127
Cash & Equivalents	147	96	221	274	165	188	154
Short-Term Investments	118	179	127	209	299	341	512
Accounts Receivable	233	195	246	217	196	215	286
Inventories, net	103	108	132	129	169	159	131
Prepaid Expenses	51	37	39	49	46	85	44
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	78	0.00	0.00
Total Noncurrent Assets	1,211	1,084	1,045	1,014	890	982	991
Goodwill	199	416	417	417	417	417	417
Intangible Assets	949	529	511	491	455	437	420
Noncurrent Deferred & Refundable Income Taxes	0.00	36	24	13	0.62	0.00	0.00
Other Noncurrent Operating Assets	62	103	93	93	17	127	155
Total Liabilities & Shareholders' Equity	1,865	1,699	1,810	1,893	1,842	1,969	2,118
Total Liabilities	1,768	1,634	1,659	1,643	1,664	1,680	1,665
Total Current Liabilities	109	92	116	115	132	133	109
Accounts Payable	18	8.70	10	19	13	15	12
Accrued Expenses	74	80	105	95	118	118	96
Total Noncurrent Liabilities	1,658	1,542	1,543	1,528	1,532	1,547	1,557
Long-Term Debt	1,491	1,494	1,496	1,498	1,501	1,503	1,504
Noncurrent Deferred & Payable Income Tax Liabilities	29	-	-	-	-	14	12
Other Noncurrent Operating Liabilities	135	45	45	28	31	31	40
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	97	66	151	249	178	289	453
Total Preferred & Common Equity	97	66	151	249	178	289	453
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	97	66	151	249	178	289	453
Common Stock	13	0.13	12	26	12	31	62
Retained Earnings	86	66	140	222	167	261	398
Accumulated Other Comprehensive Income / (Loss)	-1.84	0.02	-1.62	1.23	-1.49	-2.07	-6.94

This table displays calculated financial ratios and metrics derived from Halozyme Therapeutics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	79.28%	8.61%	115.84%	-52.04%	29.06%	36.53%	65.67%	48.91%	25.62%	22.44%
EBITDA Growth	58.28%	-162.94%	237.57%	-169.84%	7.17%	397.02%	70.24%	14.43%	34.41%	48.49%
EBIT Growth	57.12%	-202.94%	202.09%	-173.87%	1.83%	346.90%	85.06%	-3.04%	31.77%	62.54%
NOPAT Growth	56.45%	-203.11%	242.14%	-158.62%	2.48%	404.29%	210.45%	-51.41%	25.62%	61.08%
Net Income Growth	52.86%	-219.64%	161.12%	-227.57%	10.07%	278.69%	211.97%	-49.81%	39.31%	57.71%
EPS Growth	55.36%	-224.00%	155.56%	-224.44%	10.71%	282.00%	201.10%	-47.45%	45.83%	63.33%
Operating Cash Flow Growth	21.96%	-35.87%	366.07%	-136.93%	-72.57%	164.92%	439.98%	-19.81%	61.83%	23.29%
Free Cash Flow Firm Growth	-16.13%	-9.96%	327.63%	-206.08%	21.99%	136.96%	699.77%	-359.01%	144.35%	22.06%
Invested Capital Growth	64.36%	-33.32%	-176.45%	134.31%	258.63%	147.64%	84.80%	295.12%	-4.99%	2.12%
Revenue Q/Q Growth	19.30%	-8.27%	90.67%	-45.99%	-3.24%	34.09%	-4.25%	13.69%	6.22%	7.17%
EBITDA Q/Q Growth	26.26%	-28.79%	282.08%	-195.44%	-114.45%	196.37%	-7.65%	8.30%	10.56%	13.21%
EBIT Q/Q Growth	26.49%	-51.48%	227.38%	-197.54%	-116.91%	268.07%	-7.18%	7.40%	9.61%	15.31%
NOPAT Q/Q Growth	25.34%	-50.82%	275.21%	-181.68%	-89.81%	317.93%	-1.77%	-3.99%	9.86%	12.73%
Net Income Q/Q Growth	22.93%	-44.45%	171.32%	-275.86%	-80.74%	499.73%	-1.56%	-4.29%	10.90%	13.15%
EPS Q/Q Growth	0.00%	0.00%	0.00%	-409.09%	-78.57%	468.75%	-2.14%	-2.70%	12.30%	13.95%
Operating Cash Flow Q/Q Growth	-62.47%	-1.14%	483.41%	-153.06%	-76.73%	351.03%	11.80%	-0.03%	5.40%	18.89%
Free Cash Flow Firm Q/Q Growth	-70.05%	11.66%	496.01%	-127,533.84%	-34.15%	191.52%	13.50%	0.65%	5.68%	13.83%
Invested Capital Q/Q Growth	62.45%	0.03%	-54.51%	-5.12%	2.67%	23.62%	-2.57%	-1.71%	-1.30%	-1.32%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	78.35%	77.36%	90.16%	93.33%	76.76%	83.79%	81.64%	78.90%	76.80%	84.30%
EBITDA Margin	-17.85%	-43.22%	27.55%	-40.11%	-28.85%	62.76%	64.49%	49.56%	53.03%	64.31%
Operating Margin	-20.33%	-56.72%	25.58%	-45.65%	-34.50%	53.91%	62.24%	40.53%	40.71%	54.32%
EBIT Margin	-20.01%	-55.82%	26.40%	-40.66%	-30.93%	55.94%	62.49%	40.69%	42.68%	56.65%
Profit (Net Income) Margin	-23.86%	-70.23%	19.89%	-52.90%	-36.86%	48.24%	90.84%	30.62%	33.96%	43.74%
Tax Burden Percent	100.00%	101.14%	102.21%	100.67%	99.98%	99.83%	162.04%	81.20%	80.84%	79.71%
Interest Burden Percent	119.24%	124.40%	73.70%	129.22%	119.18%	86.39%	89.72%	92.68%	98.43%	96.85%
Effective Tax Rate	0.00%	0.00%	-2.21%	0.00%	0.00%	0.17%	-62.04%	18.80%	19.16%	20.29%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	-101.96%	114.14%	174.65%	26.42%	21.32%	34.88%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	-81.86%	-198.82%	120.53%	24.05%	22.08%	35.31%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	59.55%	-7.81%	56.79%	83.81%	200.75%	163.54%
Return on Equity (ROE)	-76.42%	-1,958.98%	71.60%	-35.14%	-42.41%	106.33%	231.44%	110.23%	222.07%	198.42%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	-631.24%	-214.75%	29.20%	115.10%	-92.80%	26.44%	32.78%
Operating Return on Assets (OROA)	-15.54%	-36.94%	21.39%	-12.86%	-12.05%	26.13%	32.89%	18.23%	19.80%	30.30%
Return on Assets (ROA)	-18.54%	-46.48%	16.12%	-16.73%	-14.36%	22.53%	47.82%	13.72%	15.75%	23.39%
Return on Common Equity (ROCE)	-76.42%	-1,958.98%	71.60%	-35.14%	-42.41%	106.33%	231.44%	110.23%	222.07%	198.42%
Return on Equity Simple (ROE_SIMPLE)	-74.96%	317.18%	30.22%	-32.28%	-78.72%	85.46%	204.47%	119.04%	336.00%	122.06%
Net Operating Profit after Tax (NOPAT)	-19	-58	83	-49	-47	144	447	217	273	440
NOPAT Margin	-14.23%	-39.71%	26.15%	-31.96%	-24.15%	53.82%	100.85%	32.91%	32.91%	43.29%
Net Nonoperating Expense Percent (NNEP)	-17.92%	-187.09%	-15.47%	-12.82%	-20.11%	312.95%	54.13%	2.37%	-0.75%	-0.44%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	12.96%	17.24%	23.51%
Cost of Revenue to Revenue	21.65%	22.64%	9.84%	6.67%	23.24%	16.21%	18.36%	21.10%	23.20%	15.70%
SG&A Expenses to Revenue	29.64%	31.26%	17.00%	40.04%	39.42%	17.09%	11.35%	21.74%	17.99%	15.20%
R&D to Revenue	69.03%	102.83%	47.58%	98.94%	71.84%	12.79%	8.05%	10.09%	9.21%	7.79%
Operating Expenses to Revenue	98.67%	134.09%	64.58%	138.98%	111.26%	29.89%	19.40%	38.37%	36.09%	29.98%
Earnings before Interest and Taxes (EBIT)	-27	-82	84	-62	-61	150	277	269	354	575
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-24	-63	87	-61	-57	168	286	327	440	653
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	51.59	0.00	13.84	8.50	28.31	38.22	28.74	45.31	58.26	16.72
Price to Tangible Book Value (P/TBV)	51.59	0.00	13.84	8.50	28.31	38.22	28.74	0.00	0.00	0.00
Price to Revenue (P/Rev)	16.43	8.72	9.11	13.93	13.26	21.58	12.77	11.66	5.89	5.99
Price to Earnings (P/E)	0.00	0.00	45.80	0.00	0.00	44.73	14.06	38.06	17.34	13.70
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	2.18%	0.00%	0.00%	2.24%	7.11%	2.63%	5.77%	7.30%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	93.21	35.53	32.28	17.45	6.73	4.85	5.49
Enterprise Value to Revenue (EV/Rev)	15.99	8.80	8.27	12.42	13.16	21.69	13.08	13.39	7.29	6.89
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	30.01	0.00	0.00	34.55	20.28	27.01	13.75	10.71
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	31.31	0.00	0.00	38.77	20.93	32.90	17.08	12.16
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	31.61	0.00	0.00	40.29	12.97	40.68	22.15	15.91
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	19.52	0.00	0.00	104.64	19.36	36.80	15.56	14.60
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	21.73	0.00	0.00	157.51	19.67	0.00	17.86	16.93
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.16	-6.67	0.97	0.51	4.39	2.63	4.45	8.87	17.89	4.14
Long-Term Debt to Equity	0.65	-6.13	0.60	0.14	4.17	0.00	4.00	8.79	17.89	4.14
Financial Leverage	-1.72	-4.55	-1.46	-1.08	-0.73	0.04	0.47	3.48	9.09	4.63
Leverage Ratio	4.12	42.15	4.44	2.10	2.95	4.72	4.84	8.03	14.10	8.48
Compound Leverage Factor	4.92	52.43	3.27	2.71	3.52	4.08	4.34	7.44	13.87	8.22
Debt to Total Capital	53.68%	117.64%	49.27%	33.68%	81.44%	72.45%	81.66%	89.87%	94.71%	80.54%
Short-Term Debt to Total Capital	23.55%	9.45%	18.80%	24.38%	3.95%	72.45%	8.33%	0.80%	0.00%	0.00%
Long-Term Debt to Total Capital	30.13%	108.19%	30.47%	9.29%	77.48%	0.00%	73.33%	89.07%	94.71%	80.54%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	46.32%	-17.64%	50.73%	66.32%	18.56%	27.55%	18.34%	10.13%	5.29%	19.46%
Debt to EBITDA	-2.07	-3.42	2.32	-2.07	-7.12	2.37	3.07	4.60	3.41	2.31
Net Debt to EBITDA	2.43	-0.18	-3.06	3.75	0.33	0.17	0.47	3.49	2.65	1.39
Long-Term Debt to EBITDA	-1.16	-3.14	1.43	-0.57	-6.77	0.00	2.75	4.56	3.41	2.31
Debt to NOPAT	-2.59	-3.72	2.44	-2.60	-8.51	2.76	1.96	6.93	5.49	3.43
Net Debt to NOPAT	3.04	-0.20	-3.22	4.70	0.39	0.20	0.30	5.26	4.26	2.07
Long-Term Debt to NOPAT	-1.46	-3.42	1.51	-0.72	-8.09	0.00	1.76	6.87	5.49	3.43
Altman Z-Score	6.85	-0.07	6.16	5.58	2.76	8.52	5.78	4.11	3.44	4.35
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.75	4.70	3.89	2.86	6.35	1.32	7.91	5.65	6.64	7.80
Quick Ratio	2.25	4.04	3.74	2.57	5.61	1.11	7.10	4.54	5.07	6.50
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-48	-53	120	-128	-100	37	295	-763	338	413
Operating Cash Flow to CapEx	-1,571.31%	-1,606.09%	8,710.40%	-1,061.55%	-2,114.43%	3,883.33%	20,551.82%	0.00%	2,540.68%	4,478.91%
Free Cash Flow to Firm to Interest Expense	-9.25	-2.65	5.48	-7.08	-8.57	1.81	10.34	-38.82	18.04	22.83
Operating Cash Flow to Interest Expense	-7.13	-2.52	6.10	-2.74	-7.35	2.72	10.51	12.21	20.71	26.47
Operating Cash Flow Less CapEx to Interest Expense	-7.58	-2.68	6.03	-3.00	-7.69	2.65	10.46	13.29	19.90	25.88
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.78	0.66	0.81	0.32	0.39	0.47	0.53	0.45	0.46	0.53
Accounts Receivable Turnover	6.50	6.10	16.75	5.83	4.38	3.41	4.70	4.10	3.56	3.74
Inventory Turnover	3.68	2.75	3.15	0.73	1.75	0.96	1.42	1.81	1.69	1.18
Fixed Asset Turnover	39.18	35.75	81.35	27.65	21.40	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	7.80	8.22	5.41	1.69	8.66	10.37	46.94	14.49	13.04	14.45
Days Sales Outstanding (DSO)	56.16	59.83	21.80	62.66	83.29	107.19	77.69	89.04	102.40	97.54
Days Inventory Outstanding (DIO)	99.19	132.52	115.81	500.02	208.30	379.19	257.02	201.79	216.05	308.48
Days Payable Outstanding (DPO)	46.82	44.39	67.52	216.55	42.12	35.19	7.78	25.20	28.00	25.26
Cash Conversion Cycle (CCC)	108.53	147.96	70.09	346.13	249.46	451.19	326.93	265.63	290.45	380.76
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-16	-21	-59	20	73	180	332	1,313	1,247	1,274
Invested Capital Turnover	-4.43	-7.86	-7.88	-7.84	4.22	2.12	1.73	0.80	0.65	0.81
Increase / (Decrease) in Invested Capital	29	-5.33	-38	79	52	107	152	980	-66	26
Enterprise Value (EV)	2,160	1,291	2,617	1,887	2,579	5,803	5,797	8,837	6,046	6,992
Market Capitalization	2,218	1,279	2,884	2,115	2,598	5,774	5,661	7,694	4,882	6,083
Book Value per Share	$0.34	($0.25)	$1.46	$1.72	$0.63	$1.12	$1.40	$1.26	$0.63	$2.86
Tangible Book Value per Share	$0.34	($0.25)	$1.46	$1.72	$0.63	$1.12	$1.40	($5.81)	($6.10)	($3.57)
Total Capital	93	184	411	375	494	548	1,074	1,676	1,583	1,870
Total Debt	50	217	202	126	403	397	877	1,506	1,499	1,506
Total Long-Term Debt	28	199	125	35	383	0.00	787	1,493	1,499	1,506
Net Debt	-59	12	-267	-228	-19	29	136	1,143	1,163	910
Capital Expenditures (CapEx)	2.36	3.14	1.54	4.66	4.04	1.43	1.46	-21	15	11
Debt-free, Cash-free Net Working Capital (DFCFNWC)	23	14	-13	15	56	163	158	259	298	350
Debt-free Net Working Capital (DFNWC)	131	219	456	370	477	531	899	622	634	946
Net Working Capital (NWC)	109	202	379	278	458	133	809	608	634	946
Net Nonoperating Expense (NNE)	13	45	20	32	25	15	44	15	-8.69	-4.51
Net Nonoperating Obligations (NNO)	-59	11	-267	-229	-19	29	135	1,143	1,163	910
Total Depreciation and Amortization (D&A)	2.92	18	3.62	0.84	4.08	18	8.90	59	86	78
Debt-free, Cash-free Net Working Capital to Revenue	16.91%	9.79%	-4.09%	10.19%	28.61%	60.76%	35.56%	39.20%	35.93%	34.49%
Debt-free Net Working Capital to Revenue	97.13%	149.53%	144.10%	243.64%	243.55%	198.29%	202.69%	94.16%	76.45%	93.20%
Net Working Capital to Revenue	80.94%	137.67%	119.72%	183.38%	233.58%	49.84%	182.52%	92.14%	76.45%	93.20%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.25)	($0.81)	$0.46	($0.56)	$0.00	$0.95	$2.86	$1.48	$2.13	$3.50
Adjusted Weighted Average Basic Shares Outstanding	129.06M	129.76M	136.42M	143.60M	144.33M	136.21M	140.65M	136.84M	131.93M	126.83M
Adjusted Diluted Earnings per Share	($0.25)	($0.81)	$0.45	($0.56)	($0.50)	$0.91	$2.74	$1.44	$2.10	$3.43
Adjusted Weighted Average Diluted Shares Outstanding	129.06M	129.76M	139.07M	143.60M	144.33M	141.46M	146.80M	140.61M	134.20M	129.42M
Adjusted Basic & Diluted Earnings per Share	($0.25)	($0.81)	$0.00	$0.00	($0.50)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	126.70M	127.96M	143.08M	145.03M	144.33M	135.28M	137.70M	135.37M	126.82M	123.15M
Normalized Net Operating Profit after Tax (NOPAT)	-19	-58	57	-49	-47	144	193	217	273	440
Normalized NOPAT Margin	-14.23%	-39.71%	17.91%	-31.96%	-24.15%	53.82%	43.57%	32.91%	32.91%	43.29%
Pre Tax Income Margin	-23.86%	-69.44%	19.46%	-52.54%	-36.86%	48.32%	56.06%	37.71%	42.01%	54.87%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-5.20	-4.10	3.80	-3.42	-5.21	7.35	9.72	13.66	18.86	31.79
NOPAT to Interest Expense	-3.69	-2.92	3.77	-2.69	-4.07	7.07	15.69	11.05	14.55	24.29
EBIT Less CapEx to Interest Expense	-5.65	-4.26	3.73	-3.68	-5.56	7.28	9.67	14.74	18.05	31.20
NOPAT Less CapEx to Interest Expense	-4.15	-3.07	3.70	-2.95	-4.42	7.00	15.64	12.13	13.73	23.70
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	-276.85%	116.29%	86.93%	98.95%	142.89%	56.29%

This table displays calculated financial ratios and metrics derived from Halozyme Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	80.42%	77.93%	38.25%	45.07%	3.38%	26.75%	20.81%	4.67%	34.28%	29.55%
EBITDA Growth	50.02%	42.27%	-0.38%	152.32%	-0.65%	49.75%	53.80%	19.15%	62.05%	60.26%
EBIT Growth	10.64%	32.53%	-25.45%	194.88%	10.88%	41.18%	77.06%	25.21%	82.31%	71.77%
NOPAT Growth	-68.47%	-11.82%	-33.25%	194.41%	1.93%	40.40%	87.33%	22.49%	90.71%	58.23%
Net Income Growth	-71.54%	-13.58%	-34.09%	229.53%	32.78%	47.98%	93.92%	24.74%	67.42%	60.46%
EPS Growth	-70.27%	-8.89%	-32.56%	250.00%	38.64%	56.10%	106.90%	28.57%	72.13%	65.63%
Operating Cash Flow Growth	-42.80%	-0.08%	81.94%	66.17%	90.15%	24.14%	48.83%	-16.53%	-12.87%	74.36%
Free Cash Flow Firm Growth	-3,745.63%	-1,000.44%	-685.46%	110.00%	115.45%	116.40%	116.29%	20.80%	-24.14%	-28.10%
Invested Capital Growth	291.65%	295.12%	265.57%	-2.31%	-5.38%	-4.99%	-5.36%	-2.76%	2.14%	2.12%
Revenue Q/Q Growth	37.15%	-13.15%	-10.66%	36.32%	-2.26%	6.48%	-14.85%	18.11%	25.39%	2.73%
EBITDA Q/Q Growth	149.30%	-27.99%	-7.43%	51.84%	-1.85%	8.54%	-4.92%	17.63%	33.49%	7.35%
EBIT Q/Q Growth	153.46%	-10.21%	-24.65%	71.98%	-4.70%	14.32%	-5.51%	21.62%	38.77%	7.71%
NOPAT Q/Q Growth	170.53%	-12.80%	-32.82%	85.78%	-6.34%	20.11%	-10.36%	21.47%	45.83%	-0.34%
Net Income Q/Q Growth	171.70%	-6.38%	-31.35%	88.70%	9.48%	4.34%	-10.03%	21.38%	46.94%	0.00%
EPS Q/Q Growth	175.00%	-6.82%	-29.27%	93.10%	8.93%	4.92%	-6.25%	20.00%	45.83%	0.95%
Operating Cash Flow Q/Q Growth	73.11%	18.41%	5.47%	-23.14%	98.10%	-22.70%	26.45%	-56.89%	106.79%	54.68%
Free Cash Flow Firm Q/Q Growth	13.17%	0.55%	3.00%	111.94%	34.10%	5.58%	-3.65%	-11.44%	-15.80%	0.07%
Invested Capital Q/Q Growth	0.44%	-1.71%	-2.17%	1.14%	-2.71%	-1.30%	-2.55%	3.92%	2.19%	-1.32%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	77.36%	76.79%	78.31%	77.35%	74.62%	77.27%	85.54%	82.88%	82.96%	85.89%
EBITDA Margin	56.11%	46.52%	48.20%	53.69%	53.92%	54.96%	61.37%	61.12%	65.07%	67.99%
Operating Margin	39.86%	41.05%	33.18%	42.73%	40.86%	43.92%	48.78%	50.67%	56.26%	58.89%
EBIT Margin	40.16%	41.52%	35.02%	44.18%	43.08%	46.25%	51.33%	52.85%	58.49%	61.33%
Profit (Net Income) Margin	29.49%	31.79%	24.43%	33.82%	37.88%	37.12%	39.22%	40.30%	47.23%	45.98%
Tax Burden Percent	83.62%	81.51%	75.84%	80.25%	80.42%	84.40%	80.00%	79.19%	82.96%	76.88%
Interest Burden Percent	87.82%	93.94%	92.00%	95.40%	109.34%	95.09%	95.52%	96.30%	97.33%	97.52%
Effective Tax Rate	16.38%	18.49%	24.16%	19.75%	19.58%	15.60%	20.00%	20.81%	17.04%	23.12%
Return on Invested Capital (ROIC)	23.09%	26.86%	21.70%	20.19%	19.74%	24.02%	26.95%	27.36%	34.62%	36.48%
ROIC Less NNEP Spread (ROIC-NNEP)	21.85%	26.38%	21.51%	20.09%	20.71%	24.03%	26.98%	27.40%	34.80%	36.68%
Return on Net Nonoperating Assets (RNNOA)	74.89%	91.95%	86.38%	98.79%	134.75%	218.49%	249.78%	131.96%	91.83%	169.85%
Return on Equity (ROE)	97.98%	118.80%	108.07%	118.98%	154.49%	242.50%	276.73%	159.32%	126.46%	206.32%
Cash Return on Invested Capital (CROIC)	-91.65%	-92.80%	-90.02%	21.11%	24.65%	26.44%	30.19%	28.21%	28.42%	32.78%
Operating Return on Assets (OROA)	15.29%	18.61%	17.25%	19.03%	17.90%	21.46%	25.02%	24.42%	27.63%	32.80%
Return on Assets (ROA)	11.23%	14.25%	12.04%	14.57%	15.74%	17.22%	19.12%	18.62%	22.31%	24.59%
Return on Common Equity (ROCE)	97.98%	118.80%	108.07%	118.98%	154.49%	242.50%	276.73%	159.32%	126.46%	206.32%
Return on Equity Simple (ROE_SIMPLE)	217.75%	0.00%	275.83%	154.74%	101.90%	0.00%	179.30%	116.54%	86.69%	0.00%
Net Operating Profit after Tax (NOPAT)	70	61	41	76	71	85	76	93	135	135
NOPAT Margin	33.33%	33.46%	25.16%	34.29%	32.86%	37.07%	39.02%	40.13%	46.67%	45.28%
Net Nonoperating Expense Percent (NNEP)	1.24%	0.47%	0.18%	0.10%	-0.96%	-0.01%	-0.03%	-0.04%	-0.17%	-0.20%
Return On Investment Capital (ROIC_SIMPLE)	-	3.62%	-	-	-	5.39%	-	-	-	7.22%
Cost of Revenue to Revenue	22.64%	23.21%	21.69%	22.65%	25.38%	22.73%	14.46%	17.12%	17.04%	14.11%
SG&A Expenses to Revenue	16.49%	20.80%	23.04%	17.62%	16.33%	16.35%	17.94%	15.44%	14.22%	14.18%
R&D to Revenue	7.99%	12.43%	11.09%	8.92%	8.02%	9.27%	9.76%	9.09%	6.36%	6.86%
Operating Expenses to Revenue	37.50%	35.74%	45.13%	34.61%	33.76%	33.34%	36.76%	32.21%	26.70%	27.00%
Earnings before Interest and Taxes (EBIT)	84	75	57	98	93	106	101	122	170	183
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	117	84	78	119	116	126	120	141	189	203
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	56.17	45.31	78.51	31.45	20.22	58.26	30.22	23.03	16.02	16.72
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	9.38	11.66	7.33	6.14	6.45	5.89	6.23	7.63	7.65	5.99
Price to Earnings (P/E)	25.79	38.06	28.46	20.32	19.85	17.34	16.86	19.76	18.48	13.70
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	3.88%	2.63%	3.51%	4.92%	5.04%	5.77%	5.93%	5.06%	5.41%	7.30%
Enterprise Value to Invested Capital (EV/IC)	5.01	6.73	4.97	4.54	4.79	4.85	5.28	6.05	6.27	5.49
Enterprise Value to Revenue (EV/Rev)	11.52	13.39	9.06	7.62	7.75	7.29	7.43	8.75	8.54	6.89
Enterprise Value to EBITDA (EV/EBITDA)	22.14	27.01	19.54	14.80	15.22	13.75	13.31	15.14	14.02	10.71
Enterprise Value to EBIT (EV/EBIT)	26.74	32.90	25.64	18.80	18.75	17.08	16.12	18.09	16.21	12.16
Enterprise Value to NOPAT (EV/NOPAT)	29.55	40.68	32.46	23.90	24.37	22.15	20.79	23.47	20.74	15.91
Enterprise Value to Operating Cash Flow (EV/OCF)	27.84	36.80	22.87	19.28	16.42	15.56	14.87	18.19	20.07	14.60
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	21.25	18.90	17.86	16.99	21.14	22.29	16.93
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	15.51	8.87	22.69	9.91	6.01	17.89	8.44	5.19	3.32	4.14
Long-Term Debt to Equity	15.37	8.79	22.69	9.91	6.01	17.89	8.44	5.19	3.32	4.14
Financial Leverage	3.43	3.48	4.01	4.92	6.51	9.09	9.26	4.82	2.64	4.63
Leverage Ratio	8.05	8.03	8.78	8.09	10.85	14.10	14.53	8.58	5.71	8.48
Compound Leverage Factor	7.07	7.55	8.07	7.71	11.87	13.40	13.88	8.26	5.56	8.27
Debt to Total Capital	93.94%	89.87%	95.78%	90.83%	85.74%	94.71%	89.41%	83.85%	76.87%	80.54%
Short-Term Debt to Total Capital	0.83%	0.80%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	93.11%	89.07%	95.78%	90.83%	85.74%	94.71%	89.41%	83.85%	76.87%	80.54%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	6.06%	10.13%	4.22%	9.17%	14.27%	5.29%	10.59%	16.15%	23.13%	19.46%
Debt to EBITDA	4.98	4.60	4.57	3.75	3.77	3.41	3.12	2.98	2.61	2.31
Net Debt to EBITDA	4.10	3.49	3.73	2.88	2.55	2.65	2.15	1.93	1.45	1.39
Long-Term Debt to EBITDA	4.94	4.56	4.57	3.75	3.77	3.41	3.12	2.98	2.61	2.31
Debt to NOPAT	6.65	6.93	7.59	6.06	6.03	5.49	4.87	4.62	3.86	3.43
Net Debt to NOPAT	5.48	5.26	6.19	4.65	4.08	4.26	3.36	2.99	2.15	2.07
Long-Term Debt to NOPAT	6.59	6.87	7.59	6.06	6.03	5.49	4.87	4.62	3.86	3.43
Altman Z-Score	2.72	3.76	2.85	2.86	3.06	2.97	3.20	3.73	4.16	3.73
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.97	5.65	6.69	6.58	7.63	6.64	6.64	7.41	10.36	7.80
Quick Ratio	4.56	4.54	5.12	5.11	6.08	5.07	5.01	5.58	8.75	6.50
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-925	-920	-892	107	143	151	145	129	108	108
Operating Cash Flow to CapEx	6,908.23%	0.00%	764.38%	0.00%	4,497.66%	3,942.76%	3,650.97%	2,160.88%	7,605.54%	5,847.54%
Free Cash Flow to Firm to Interest Expense	-90.43	-201.24	-196.36	23.71	31.71	28.89	32.24	28.45	23.95	23.88
Operating Cash Flow to Interest Expense	6.81	18.04	19.14	14.87	29.39	19.61	28.72	12.33	25.50	39.31
Operating Cash Flow Less CapEx to Interest Expense	6.71	19.71	16.64	15.23	28.74	19.11	27.93	11.76	25.17	38.64
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.38	0.45	0.49	0.43	0.42	0.46	0.49	0.46	0.47	0.53
Accounts Receivable Turnover	3.36	4.10	4.57	3.55	3.47	3.56	4.42	3.79	3.77	3.74
Inventory Turnover	1.49	1.81	2.04	1.52	1.57	1.69	1.34	1.20	1.30	1.18
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	11.05	14.49	31.83	15.63	9.72	13.04	16.85	13.70	10.70	14.45
Days Sales Outstanding (DSO)	108.57	89.04	79.90	102.74	105.34	102.40	82.64	96.28	96.91	97.54
Days Inventory Outstanding (DIO)	244.71	201.79	178.74	240.32	232.60	216.05	271.57	304.12	280.04	308.48
Days Payable Outstanding (DPO)	33.02	25.20	11.47	23.35	37.55	28.00	21.66	26.64	34.12	25.26
Cash Conversion Cycle (CCC)	320.25	265.63	247.17	319.71	300.39	290.45	332.55	373.76	342.83	380.76
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,335	1,313	1,284	1,299	1,264	1,247	1,215	1,263	1,291	1,274
Invested Capital Turnover	0.69	0.80	0.86	0.59	0.60	0.65	0.69	0.68	0.74	0.81
Increase / (Decrease) in Invested Capital	994	980	933	-31	-72	-66	-69	-36	27	26
Enterprise Value (EV)	6,687	8,837	6,388	5,897	6,054	6,046	6,411	7,638	8,089	6,992
Market Capitalization	5,448	7,694	5,170	4,750	5,039	4,882	5,374	6,664	7,251	6,083
Book Value per Share	$0.70	$1.26	$0.49	$1.15	$1.89	$0.63	$1.40	$2.27	$3.57	$2.86
Tangible Book Value per Share	($7.63)	($5.81)	($6.49)	($5.90)	($4.99)	($6.10)	($5.47)	($4.44)	($3.03)	($3.57)
Total Capital	1,601	1,676	1,560	1,647	1,747	1,583	1,679	1,792	1,957	1,870
Total Debt	1,504	1,506	1,494	1,496	1,498	1,499	1,501	1,503	1,504	1,506
Total Long-Term Debt	1,491	1,493	1,494	1,496	1,498	1,499	1,501	1,503	1,504	1,506
Net Debt	1,239	1,143	1,219	1,148	1,014	1,163	1,037	973	838	910
Capital Expenditures (CapEx)	1.01	-7.64	11	-1.62	2.94	2.60	3.55	2.58	1.52	3.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)	292	259	247	301	281	298	278	325	352	350
Debt-free Net Working Capital (DFNWC)	557	622	523	649	764	634	742	854	1,018	946
Net Working Capital (NWC)	544	608	523	649	764	634	742	854	1,018	946
Net Nonoperating Expense (NNE)	8.02	3.03	1.19	1.04	-11	-0.12	-0.39	-0.40	-1.62	-2.09
Net Nonoperating Obligations (NNO)	1,238	1,143	1,218	1,148	1,014	1,163	1,037	973	838	910
Total Depreciation and Amortization (D&A)	33	9.07	21	21	23	20	20	19	19	20
Debt-free, Cash-free Net Working Capital to Revenue	50.21%	39.20%	35.11%	38.92%	35.93%	35.93%	32.27%	37.26%	37.14%	34.49%
Debt-free Net Working Capital to Revenue	95.95%	94.16%	74.20%	83.93%	97.84%	76.45%	85.97%	97.84%	107.47%	93.20%
Net Working Capital to Revenue	93.66%	92.14%	74.20%	83.93%	97.84%	76.45%	85.97%	97.84%	107.47%	93.20%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.45	$0.43	$0.29	$0.57	$0.62	$0.65	$0.61	$0.73	$1.08	$1.08
Adjusted Weighted Average Basic Shares Outstanding	136.53M	136.84M	135.03M	131.73M	131.97M	131.93M	126.94M	127.12M	126.85M	126.83M
Adjusted Diluted Earnings per Share	$0.44	$0.41	$0.29	$0.56	$0.61	$0.64	$0.60	$0.72	$1.05	$1.06
Adjusted Weighted Average Diluted Shares Outstanding	139.39M	140.61M	137.90M	133.54M	134.08M	134.20M	128.89M	129.22M	130.13M	129.42M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	135.21M	135.37M	131.68M	131.92M	132.10M	126.82M	127.27M	126.68M	127.23M	123.15M
Normalized Net Operating Profit after Tax (NOPAT)	70	61	41	76	71	85	76	93	135	135
Normalized NOPAT Margin	33.33%	33.46%	25.16%	34.29%	32.86%	37.07%	39.02%	40.13%	46.67%	45.28%
Pre Tax Income Margin	35.27%	39.00%	32.22%	42.14%	47.10%	43.98%	49.02%	50.89%	56.93%	59.80%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	8.21	16.49	12.50	21.73	20.66	20.38	22.31	27.03	37.50	40.25
NOPAT to Interest Expense	6.81	13.29	8.98	16.87	15.76	16.34	16.96	20.52	29.93	29.72
EBIT Less CapEx to Interest Expense	8.11	18.16	9.99	22.09	20.00	19.88	21.52	26.46	37.17	39.58
NOPAT Less CapEx to Interest Expense	6.71	14.96	6.48	17.23	15.11	15.84	16.17	19.95	29.59	29.05
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	170.61%	98.95%	192.74%	149.80%	59.11%	142.89%	79.14%	74.80%	64.29%	56.29%

Frequently Asked Questions About Halozyme Therapeutics' Financials

When does Halozyme Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Halozyme Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Halozyme Therapeutics' net income changed over the last 9 years?

Halozyme Therapeutics' net income appears to be on an upward trend, with a most recent value of $444.09 million in 2024, falling from -$32.23 million in 2015. The previous period was $281.59 million in 2023.

What is Halozyme Therapeutics's operating income?

Halozyme Therapeutics's total operating income in 2024 was $551.48 million, based on the following breakdown:

Total Gross Profit: $855.91 million
Total Operating Expenses: $304.43 million

How has Halozyme Therapeutics revenue changed over the last 9 years?

Over the last 9 years, Halozyme Therapeutics' total revenue changed from $135.06 million in 2015 to $1.02 billion in 2024, a change of 651.8%.

How much debt does Halozyme Therapeutics have?

Halozyme Therapeutics' total liabilities were at $1.70 billion at the end of 2024, a 3.0% increase from 2023, and a 1,124.6% increase since 2015.

How much cash does Halozyme Therapeutics have?

In the past 9 years, Halozyme Therapeutics' cash and equivalents has ranged from $43.29 million in 2015 to $234.20 million in 2022, and is currently $115.85 million as of their latest financial filing in 2024.

How has Halozyme Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, Halozyme Therapeutics' book value per share changed from 0.34 in 2015 to 2.86 in 2024, a change of 751.3%.

Remove Ads

Related Companies

This page (NASDAQ:HALO) was last updated on 4/16/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Halozyme Therapeutics (HALO) Financials

Frequently Asked Questions About Halozyme Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Halozyme Therapeutics (HALO) Financials

Annual Income Statements for Halozyme Therapeutics

Quarterly Income Statements for Halozyme Therapeutics

Annual Cash Flow Statements for Halozyme Therapeutics

Quarterly Cash Flow Statements for Halozyme Therapeutics

Annual Balance Sheets for Halozyme Therapeutics

Quarterly Balance Sheets for Halozyme Therapeutics

Annual Metrics and Ratios for Halozyme Therapeutics

Quarterly Metrics and Ratios for Halozyme Therapeutics

Frequently Asked Questions About Halozyme Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools